Haleon Plc - ADR [HLN] vs Regencell Bioscience [RGC] Detailed Stock Comparison

Haleon Plc - ADR

NYSE
Loading...

Regencell Bioscience Holdings Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Haleon Plc - ADR wins in 13 metrics, Regencell Bioscience Holdings Ltd. wins in 2 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Haleon Plc - ADR Regencell Bioscience Holdings Ltd. Better
P/E Ratio (TTM) 18.72 -3,258.62 Haleon Plc - ADR
Price-to-Book Ratio 1.88 2,929.00 Haleon Plc - ADR
Debt-to-Equity Ratio 52.37 11.20 Regencell Bioscience Holdings Ltd.
PEG Ratio 15.42 N/A N/A
EV/EBITDA 33.08 -3,921.47 Haleon Plc - ADR
Profit Margin (TTM) 15.11% 0.00% Haleon Plc - ADR
Operating Margin (TTM) 23.17% 0.00% Haleon Plc - ADR
EBITDA Margin (TTM) 23.17% N/A N/A
Return on Equity 10.27% -54.81% Haleon Plc - ADR
Return on Assets (TTM) 4.67% -33.20% Haleon Plc - ADR
Free Cash Flow (TTM) $2.22B $-4.01M Haleon Plc - ADR
Dividend Yield 1.63% N/A N/A
1-Year Return -16.01% 20.24% Regencell Bioscience Holdings Ltd.
Price-to-Sales Ratio (TTM) 3.78 N/A N/A
Enterprise Value $122.54B $14.48B Haleon Plc - ADR
EV/Revenue Ratio 8.23 N/A N/A
Gross Profit Margin (TTM) 55.38% N/A N/A
Revenue per Share (TTM) $2 $0 Haleon Plc - ADR
Earnings per Share (Diluted) $0.50 $-0.01 Haleon Plc - ADR
Beta (Stock Volatility) 0.33 2.25 Haleon Plc - ADR
Short % of Float 0.43% 1.26% Haleon Plc - ADR

Haleon Plc - ADR vs Regencell Bioscience Holdings Ltd. Stock Performance Analysis

Loading Price Chart...

HLN
RGC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%
Regencell Bioscience Holdings Ltd.-9.24%-20.10%-40.20%-24.65%-0.98%-16.80%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%
Regencell Bioscience Holdings Ltd.20.24%2,888.89%6,625.00%6,625.00%6,625.00%6,625.00%

Performance & Financial Health Analysis: Haleon Plc - ADR vs Regencell Bioscience Holdings Ltd.

MetricHLNRGC
Market Information
Market Cap i$42.40B$14.00B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,594,249105,478
90 Day Avg. Volume i7,985,230162,743
Last Close$9.07$17.09
52 Week Range$8.65 - $11.28$9.39 - $83.60
% from 52W High-19.59%-79.56%
All-Time High$11.42 (Jun 02, 2025)$950.00 (May 30, 2025)
% from All-Time High-20.58%-98.20%
Growth Metrics
Quarterly Revenue Growth0.01%N/A
Quarterly Earnings Growth0.86%N/A
Financial Health
Profit Margin (TTM) i0.15%0.00%
Operating Margin (TTM) i0.23%0.00%
Return on Equity (TTM) i0.10%-0.55%
Debt to Equity (MRQ) i52.3711.20
Cash & Liquidity
Book Value per Share (MRQ)$4.99$0.01
Cash per Share (MRQ)$0.15$0.01
Operating Cash Flow (TTM) i$3.56B$-3,113,576
Levered Free Cash Flow (TTM) i$1.89B$-1,507,277
Dividends
Last 12-Month Dividend Yield i1.63%N/A
Last 12-Month Dividend i$0.17N/A

Valuation & Enterprise Metrics Analysis: Haleon Plc - ADR vs Regencell Bioscience Holdings Ltd.

MetricHLN (Apr 24, 2026)RGC (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i18.72-3,258.62
Forward P/E i15.42N/A
PEG Ratio i15.42N/A
Price to Sales (TTM) i3.78N/A
Price to Book (MRQ) i1.882,929.00
Market Capitalization
Market Capitalization i$42.40B$14.00B
Enterprise Value i$122.54B$14.48B
Enterprise Value Metrics
Enterprise to Revenue i8.23N/A
Enterprise to EBITDA i33.08-3,921.47
Risk & Other Metrics
Beta i0.332.25
Book Value per Share (MRQ) i$4.99$0.01

Financial Statements Comparison: Haleon Plc - ADR vs Regencell Bioscience Holdings Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHLN (2025)RGC (2024)
Revenue/Sales i11.03B0
Cost of Goods Sold i3.95BN/A
COGS % of Revenue i35.8%-
Gross Profit i7.08BN/A
Gross Margin i64.2%-
Research & Development i316.00M1.07M
Operating Income (EBIT) i2.41B-4.74M
Operating Margin i21.9%-
EBITDA i2.81B-3.99M
EBITDA Margin i25.5%-
Pre-Tax Income i2.15B-4.36M
Pre-Tax Income % of Revenue i19.5%-
Income Tax i472.00M0
Income Tax % of Revenue i4.3%-
Net Income (Profit) i1.68B-4.36M
Profit Margin i15.2%-

Balance Sheet & Liquidity Metrics

MetricHLN (2025)RGC (2024)
Cash & Equivalents i1.26B2.96M
Total Current Assets i4.55B8.11M
Total Current Assets % of Revenue i41.3%-
Total Current Liabilities i4.93B193,578
Total Current Liabilities % of Revenue i44.7%-
Long-Term Debt i7.75B25,934
Long-Term Debt % of Revenue i70.2%-
Total Shareholders Equity i16.48B8.22M
Retained Earnings i27.85B-21.62M
Retained Earnings % of Revenue i252.5%-
Property, Plant & Equipment i1.00M84,780

Cash Flow Statement Comparison

MetricHLN (2025)RGC (2024)
Operating Cash Flow i2.19B-3.88M
Operating Cash Flow % of Revenue i19.8%-
Capital Expenditures i-322.00M-5,376
Free Cash Flow i2.22B-4.01M
FCF Margin i20.1%-
Debt Repayment i-1.35BN/A
Common Stock Repurchase i-654.00MN/A

Short Interest & Institutional Ownership Analysis

MetricHLNRGC
Shares Short i19.28M700,509
Short Ratio i2.145.62
Short % of Float i0.43%1.26%
Shares Outstanding i8.91B494.49M
Float Shares i8.86B43.94M
% Held by Insiders i0.01%88.56%
% Held by Institutions i12.74%0.12%
% Held by Public i87.25%11.32%

Dividend Analysis & Yield Comparison: Haleon Plc - ADR vs Regencell Bioscience Holdings Ltd.

MetricHLNRGC
Last 12-Month Dividend i$0.17N/A
Last 12-Month Dividend Yield i1.63%N/A
3-Year Avg Annual Dividend i$0.11N/A
3-Year Avg Dividend Yield i0.91%N/A
3-Year Total Dividends i$0.34N/A
Ex-Dividend DateApr 25, 2025N/A